NEP1-40, a competitive antagonist peptide of the Nogo/NgR pathway, is previously shown to promote axon regeneration and improve outcome after spinal cord injury and stroke in vivo [33, 39, 40]. This evidence concerns the gene EMG1 and stroke disorder.